On September 29, Hu Xinbao, Party Secretary and Chairman of Hunan Pharmaceutical Development Group, led an inspection team to the company's Liuyang production base to oversee safety production and operational management, followed by a safety production coordination meeting. Accompanying the inspection were Zhao Zhihai, Deputy General Manager and Party Committee member of the Group; Zhang Yunlong, Deputy Director of the Party-Mass Affairs Department; and Li Zuo, Deputy Director of the Enterprise Management Department. The company's Party Branch Secretary and Chairman Shen Fanshun, along with the management team and heads of relevant departments, participated in the inspection.

Hu Xinbao and his delegation conducted on-site inspections at multiple facilities including the traditional Chinese medicine formula granules extraction workshop, raw material warehouse, traceability intelligent automation workshop, herbal decoction pieces workshop, and ultra-fine food workshop. The inspections focused on compliance with regulations, operational procedures, fire safety equipment, and implementation of production safety responsibilities. At the subsequent safety production coordination meeting, Shen Fanshun delivered a detailed report on the company's safety performance and business operations during the first three quarters. Zhao Zhihai outlined key requirements for safety and production management: 1) Maintain the morning meeting system to emphasize safety awareness and communication; 2) Conduct irregular inspections to identify and rectify potential hazards, establish detailed records for safety improvements, assign responsibilities to individuals, and fully recognize the critical importance of current safety measures; 3) Set clear targets for achieving production efficiency goals, optimize product structures, adjust strategies, and enhance cost-effectiveness in procurement management.

In his concluding remarks, Hu Xinbao commended the company's standardized safety management practices. Addressing next-phase priorities based on on-site inspection findings, he outlined five key initiatives: 1) Refining safety protocols to promptly identify and eliminate hazards, ensuring zero safety incidents through systematic measures. 2) Establishing routine safety awareness programs, incorporating safety briefings into daily workshop meetings, and strictly enforcing established safety regulations. 3) Strategic planning for the 15th Five-Year Plan period, emphasizing chain enhancement, extension, and strengthening across the traditional Chinese medicine industry chain. 4) Strengthening core competencies through product innovation and optimized supply chain services. 5) Continuously improving management efficiency and operational mechanisms via institutional reforms. 6) Talent development strategies including emotional engagement, career opportunities, and competitive compensation packages, with bold recruitment of young professionals through initiatives like the "Elite Training Program" and "Outstanding Talent Development Program." The meeting also addressed production capacity optimization, inspection compliance, and long-term strategic planning.